Last $13.85 USD
Change Today +0.54 / 4.06%
Volume 1.0M
VNDA On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

vanda pharmaceuticals inc (VNDA) Snapshot

Open
$13.29
Previous Close
$13.31
Day High
$13.98
Day Low
$12.57
52 Week High
03/24/14 - $19.25
52 Week Low
04/17/13 - $4.41
Market Cap
469.1M
Average Volume 10 Days
1.3M
EPS TTM
$-0.66
Shares Outstanding
33.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VANDA PHARMACEUTICALS INC (VNDA)

vanda pharmaceuticals inc (VNDA) Related Businessweek News

No Related Businessweek News Found

vanda pharmaceuticals inc (VNDA) Details

Vanda Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development and commercialization of pharmaceutical products. Its product portfolio includes HETLIOZ, a product for the treatment of Non-24-Hour Sleep-Wake Disorder; Fanapt, a product for the treatment of schizophrenia; and VLY-686, a small molecule neurokinin-1 receptor antagonist. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

53 Employees
Last Reported Date: 02/25/14
Founded in 2002

vanda pharmaceuticals inc (VNDA) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $515.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $315.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $279.8K
Compensation as of Fiscal Year 2013.

vanda pharmaceuticals inc (VNDA) Key Developments

Vanda Pharmaceuticals, Inc. Announces Availability of HETLIOZ for Non-24-Hour Sleep-Wake Disorder

Vanda Pharmaceuticals, Inc. announced the availability of HETLIOZ. HETLIOZ is the first treatment approved by the U.S Food and Drug Administration (FDA) for Non-24-Hour Sleep-Wake Disorder (Non-24), a serious chronic circadian rhythm disorder that affects up to 70% of people who are totally blind. Vanda has launched HETLIOZSolutions to support and facilitate the treatment of totally blind people living with Non-24. HETLIOZSolutions will provide patients with a host of resources including information about Non-24 and HETLIOZ, insurance support, overview of financial assistance programs, and pharmacy access. HETLIOZ, which was approved by the FDA in January 2014, is available through specialty pharmacies in the U.S.

Vanda Pharmaceuticals, Inc. Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Full Year Ended December 31, 2013

Vanda Pharmaceuticals, Inc. announced unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2013. Total revenues for the fourth quarter of 2013 were $8.8 million, compared to $7.9 million for the fourth quarter of 2012. Fourth quarter 2013 revenues included $2.0 million in Fanapt(R) royalties received from Novartis as compared to royalties of $1.2 million for the fourth quarter of 2012. Vanda recorded a net loss of $7.6 million for the fourth quarter of 2013, compared to a net loss of $6.4 million for the fourth quarter of 2012. Diluted net loss per share for the fourth quarter of 2013 and 2012 was $0.23 per share. Loss from operations was $7,667,000 against $6,428,000 for the same period of last year. Loss before tax benefit was $7,623,000 against $6,369,000 for the same period of last year. Total revenues for the full year 2013 were $33.9 million, compared to $32.7 million for 2012. Full year 2013 revenues included $7.1 million in Fanapt(R) royalties received from Novartis as compared to royalties of $5.9 million for the prior year. Both 2013 and 2012 revenues include $26.8 million recognized from the $200.0 million upfront payment previously received from Novartis for Fanapt(R) U.S. and Canadian rights. Vanda recorded a net loss of $20.3 million for 2013, compared to a net loss of $27.7 million for 2012. Diluted net loss per share for 2013 was $0.67, compared to a diluted net loss per share of $0.98 for 2012. Loss from operations was $20,400,000 against $28,225,000 for the same period of last year. Loss before tax benefit was $20,255,000 against $27,664,000 for the same period of last year.

FDA Approves Vanda Pharmaceuticals Inc.'s HETLIOZ(TM) (Tasimelteon) for Treatment of Non-24-Hour Sleep-Wake Disorder

Vanda Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has approved HETLIOZ(TM) (tasimelteon) 20mg capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ(TM) is the FDA approved medication for Non-24. Non-24 was described more than 60 years ago, and is a chronic, circadian rhythm disorder resulting from the misalignment of the endogenous master body clock to the 24-hour day, disrupting the sleep-wake cycle. Non-24 affects the majority of totally blind individuals and it is estimated that approximately 80,000 Americans have the disorder. The approval of HETLIOZ(TM) was based on two key efficacy studies and the safety has been evaluated in over 1,300 individuals. The most common adverse reactions in the clinical trials were headache, increased alanine aminotransferase, nightmares or unusual dreams, upper respiratory or urinary tract infection. After taking HETLIOZ(TM), patients should limit their activity to preparing for going to bed because HETLIOZ(TM) can impair the performance of activities requiring complete mental alertness.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNDA:US $13.85 USD +0.54

VNDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 3,759 GBp +35.50
Dainippon Sumitomo Pharma Co Ltd ¥1,573 JPY -22.00
Eli Lilly & Co $59.96 USD +0.54
Pfizer Inc $30.09 USD +0.20
Sanofi €74.77 EUR +0.75
View Industry Companies
 

Industry Analysis

VNDA

Industry Average

Valuation VNDA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.1x
Price/Book 10.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.5x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VANDA PHARMACEUTICALS INC, please visit www.vandapharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.